Overview

A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Status:
RECRUITING

Trial end date:
2030-10-27

Target enrollment:

Participant gender:

Summary

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding MK-1084 (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. MK-1084 and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of MK-1084 with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive MK-1084 with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Bevacizumab
Cetuximab
Fluorouracil
Leucovorin
Oxaliplatin